Business / Finance

RSS

FTC votes to approve Watson's acquisition of Actavis

Watson Pharmaceuticals, Inc. today announced that the Federal Trade Commission (FTC) has voted to approve Watson's acquisition of the Actavis group of companies.

16 Oct 2012

Wise Foundation announces name change

The Wise Foundation has announced the transition to its new name, the Association for Vascular Access (AVA) Foundation. The new name better emphasizes the organization's bond with its parent organization, the Association for Vascular Access.

16 Oct 2012

Taking technology from the lab to the patient: SMART Arm™: Hand of hope for stroke survivors

Creating a viable commercial product from its beginnings as a research concept through to a final product patients can use is a long, difficult and often expensive process. However, as David Henderson, the Managing Director of UniQuest, one of the leading technology transfer companies in the Asia Pacific region explains, a focus on patient needs is vital for developing a successful product.

15 Oct 2012

Critical Diagnostics signs agreements with four new European distributors

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases, today announced that it has signed agreements with four new European distributors in Germany, Spain, France and Turkey.

15 Oct 2012

KYTHERA prices initial public offering of 4,400,000 shares of common stock

KYTHERA Biopharmaceuticals, Inc. today announced the pricing of its initial public offering of 4,400,000 shares of its common stock at a price to the public of $16.00 per share.

11 Oct 2012

Theragenics enters second amended and restated credit agreement with Wells Fargo

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has entered into a Second Amended and Restated Credit Agreement with Wells Fargo Bank, National Association.

11 Oct 2012

Beekman closes sale of Northwestern Management Services

The Beekman Group announced the closing of the sale of Northwestern Management Services, LLC to Linden Capital Partners, a leading healthcare-focused middle market investment firm.

11 Oct 2012

Genocea raises $30M in Series C financing round

Genocea Biosciences, Inc., a clinical-stage company advancing innovative T cell vaccines for infectious diseases, has raised $30 million in a Series C financing round.

10 Oct 2012

Biomet first quarter net sales increase 6% to $707.4 million

Biomet, Inc. announced today financial results for its first fiscal quarter ended August 31, 2012.

10 Oct 2012

Boston Scientific enters definitive agreement to acquire Rhythmia Medical

Boston Scientific Corporation has entered into a definitive agreement to acquire privately-held Rhythmia Medical, Inc., a developer of next-generation mapping and navigation solutions for use in cardiac catheter ablations and other electrophysiology procedures, including atrial fibrillation and atrial flutter.

9 Oct 2012

UnitedHealth to buy Brazilian health insurer

UnitedHealth Group Inc., the biggest U.S. health insurance company, agreed to pay about $4.9 billion to buy 90 percent of Amil Participacoes SA (AMIL3), a Brazil-based insurer and hospitals operator that gives the American company a stake in the world's second-biggest emerging economy.

8 Oct 2012

FCP reports launch of comprehensive pharmacy services company, AlixaRx

Fillmore Capital Partners, a private investment company, today announced the formal launch of AlixaRx, a company that has been in development over the past four years. AlixaRx will provide comprehensive pharmacy services to post-acute and numerous other healthcare settings.

8 Oct 2012

EC approves Watson's pending acquisition of Actavis

Watson Pharmaceuticals, Inc. today announced that the European Commission has approved the company's pending acquisition of the privately held Actavis Group.

6 Oct 2012

Contract Manufacturing Offering introduced to the biopharmaceutical market by Olympus Biotech

Olympus Biotech, an Olympus Corporation company, today announced its new Contract Manufacturing Offering (CMO) at its state-of-the-art facility in Lebanon, New Hampshire.

From Evident Corporation - Life Sciences 5 Oct 2012

Bristol-Myers Squibb, Sanofi restructure long-term alliance

Sanofi and Bristol-Myers Squibb Company today announced they have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.

4 Oct 2012

Adolescent and young cancer cost barriers: an interview with Anne Kirchhoff

According to the National Cancer Institute, almost 70,000 people ages 15-39 are diagnosed with cancer each year in the United States. Cancers in this adolescent and young adult (AYA) population differ quite a bit across this age span.

3 Oct 2012

Washington Post buys major stake in Celtic Healthcare Inc.; Tenet plans buybacks

Post Co. said Monday it would buy a majority stake in Celtic Healthcare Inc., a closely held provider of hospice and home health care in Pennsylvania and Maryland. Terms of the deal weren't disclosed, although one analyst, Sheryl Skolnick of CRT Capital Group, said average valuations suggests the deal could have been worth at least $50 million. That is a drop in the bucket for Post Co., which has a market capitalization of $2.7 billion.

3 Oct 2012

Humble Surgical Hospital acquires Mazor Robotics’ Renaissance system

Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced that Humble Surgical Hospital in Humble, Texas acquired its Renaissance system.

3 Oct 2012

Alimera completes $40 million convertible preferred stock sale

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has completed the sale of $40 million of Series A Convertible Preferred Stock and warrants to purchase Series A Preferred to a group of institutional investors, including both existing and new investors, in a private placement.

3 Oct 2012

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012